Tofacitinib
Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis
June 20, 2018Tofacitinib may provide a fast and prolonged analgesic effect in patients with rheumatoid arthritis or psoriatic arthritis who are unresponsive to csDMARD or to TNFi, as well as in individuals with ankylosing spondylitis.
Tocilizumab Linked to Anemia Marker Improvement in Rheumatoid Arthritis
September 11, 2017Tocilizumab was associated with significant improvements in hemoglobin and hematocrit over 2 years of treatment in patients with rheumatoid arthritis.
Low Disease Activity in Rheumatoid Arthritis After Tofacitinib Discontinuation
June 01, 2017Approximately 1 in 3 patients with RA who discontinued tofacitinib maintained low disease activity after 1 year.
Clinical Pain Advisor Articles
- IASP Updates Classification of Chronic Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- OnabotulinumtoxinA Therapy May Reduce Frequency, Severity of New Daily Persistent Headache
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Psychological Comorbidities in Chronic Pelvic Pain
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Private Equity Acquisition of Physician Practices Discussed
- Many Adults in 50s, Early 60s Worried About Health Insurance
- Social Media and the Spread of Misinformation: Taking Back Public Health
